نتائج البحث - Erika Hamilton

تنقيح النتائج
  1. 1
    Targeting CDK4/6 in patients with cancer

    Targeting CDK4/6 in patients with cancer حسب Erika Hamilton, Jeffrey R. Infante

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Targeting HER2-positive breast cancer: advances and future directions

    Targeting HER2-positive breast cancer: advances and future directions حسب Sandra M. Swain, Mythili Shastry, Erika Hamilton

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer

    Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer حسب Mythili Shastry, Saya Jacob, Hope S. Rugo, Erika Hamilton

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

    PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer حسب Erika Hamilton, Rinath Jeselsohn, Linda T. Vahdat, Sara A. Hurvitz

    منشور في 2025
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role

    Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging... حسب Maxwell R. Lloyd, Seth A. Wander, Erika Hamilton, Pedram Razavi, Aditya Bardia

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Rise of Antibody-Drug Conjugates: The Present and Future

    Rise of Antibody-Drug Conjugates: The Present and Future حسب Mythili Shastry, Avantika Gupta, Sarat Chandarlapaty, Matthew R. Young, Thomas Powles, Erika Hamilton

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

    Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity حسب Devalingam Mahalingam, Judy S. Wang, Erika Hamilton, John Sarantopoulos, John Nemunaitis, Garry Weems, Laura Carter, Xiao Hu, Marshall T. Schreeder, H. Jeffrey Wilkins

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

    nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HE... حسب Erika Hamilton, Javier Cortés, Özgür Özyılkan, Shin‐Cheh Chen, Katarína Petráková, Alexey Manikhas, Guy Jérusalem, Roberto Hegg, Jens Huober, Wei Zhang, Yanyun Chen, Miguel Martín

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing

    Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing حسب Christina I. Herold, Vijaya Chadaram, Bercedis L. Peterson, P. Kelly Marcom, Judith O. Hopkins, Gretchen Kimmick, Justin Favaro, Erika Hamilton, Renee Welch, Sarah Bacus, Kimberly Blackwell

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

    Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes حسب Timothy A. Yap, Erika Hamilton, Todd M. Bauer, Ecaterina E. Dumbrava, Rinath Jeselsohn, Aaron Enke, Sabrina Hurley, Kevin K. Lin, Jenn Habeck, Heidi Giordano, Geoffrey I. Shapiro

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up

    Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up حسب Sylvia Adams, Jennifer R. Diamond, Erika Hamilton, Paula R. Pohlmann, Sara M. Tolaney, Ching‐Wei Chang, Wei Zhang, Koho Iizuka, Paul Foster, Luciana Molinero, Roel Funke, John D. Powderly

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer حسب Mark D. Pegram, Erika Hamilton, Antoinette R. Tan, Anna Maria Storniolo, Kemal Balic, Anton I. Rosenbaum, Meina Liang, Peng He, Shannon Marshall, Anita Scheuber, Mayukh Das, Manish R. Patel

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

    A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer حسب Erika Hamilton, Manish R. Patel, Anne Armstrong, Richard D. Baird, Komal Jhaveri, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Shethah Morgan, Gaia Schiavon, Hazel M. Weir, Seock‐Ah Im

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer

    273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer حسب Erika Hamilton, Javier Cortés, Özgür Özyılkan, S-C. Chen, Katarína Petráková, Alexey Manikhas, Guy Jérusalem, Roberto Hegg, Jens Huober, Sonya C. Chapman, Zhengyu Yang, Yongmei Chen, Erica L. Johnston, Miguel Martín

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

    The evolution of cyclin dependent kinase inhibitors in the treatment of cancer حسب Komal Jhaveri, Howard A Burris rd, Timothy A. Yap, Erika Hamilton, Hope S. Rugo, Jonathan W. Goldman, Stephen G. Dann, Feng Liu, Gilbert Y. Wong, Heike I. Krupka, Geoffrey I. Shapiro

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07)

    185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in... حسب C. Anders, S. Loi, Erika Hamilton, Komal Jhaveri, P. Schmid, Erhan Gökmen, S-A. Im, Cengiz Karaçin, Carlos H. Barrios, Y.H. Park, S. Uzunoğlu, Sarah E. Boston, Adam Konpa, S. Mondal, Fabrice André

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

    PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors حسب Timothy A. Yap, Atish D. Choudhury, Erika Hamilton, Lee S. Rosen, Kayla Stratton, M. Gordon, David Schaer, Lei Liu, L. Zhang, Rajendar K. Mittapalli, Wei Zhong, N. Soman, A. W. Tolcher

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

    Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion حسب Erika Hamilton, Kimberly Blackwell, Amy Hobeika, Timothy M. Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frédéric Lehmann, Neil L. Spector, Jun-Ping Wei, Takuya Osada, H. Kim Lyerly

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer حسب Siqing Fu, Bradley R. Corr, Kerry Culm-Merdek, Colleen Mockbee, Hagop Youssoufian, Robert Stagg, R. Wendel Naumann, Robert M. Wenham, Rafael D. Rosengarten, Laura E. Benjamin, Erika Hamilton, Kathleen N. Moore

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer

    First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer حسب Nehal J. Lakhani, Daphne Stewart, Debra L. Richardson, Lauren Dockery, Linda Van Le, Justin Call, Fatima Rangwala, Guanfang Wang, Bo Ma, Simon Metenou, Jade Huguet, Elliot Offman, Lini Pandite, Erika Hamilton

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: